Overview

Urinary Biomarker Study With Sulindac and Difluoromethylornithine

Status:
Withdrawn
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the effects of 2 drugs (sulindac and Difluoromethylornithine (DFMO)) either alone or in combination on biomarkers found in urine.
Phase:
Phase 2
Details
Lead Sponsor:
Cancer Prevention Pharmaceuticals, Inc.
Collaborator:
University of Arizona
Treatments:
Eflornithine
Sulindac